Back to top
more

Allergan plc (AGN)

(Delayed Data from NYSE)

$145.81 USD

145.81
1,518,334

+1.56 (1.08%)

Updated May 3, 2019 04:01 PM ET

After-Market: $145.88 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Intercept (ICPT) Stock Loses Sheen in 2017: What Lies Ahead?

Intercept (ICPT) had a tough time in 2017 after news of death were out related to lead drug's Ocaliva's dosing. We do not expect a phenomenal revival in 2018 either.

    Allergan/Paratek's Acne Candidate NDA Filing Accepted by FDA

    Allergan (AGN) and partner Paratek announces that its new drug application for Seysara has been accepted for review by the FDA for moderate to severe acne vulgaris.

      Allergan's Vraylar Positive for Bipolar Disease in Phase III

      Allergan (AGN) releases positive top-line results from a phase III study on Vraylar for treatment of bipolar I depression. The trial meets its primary endpoints with significant progress in patients.

        Teva's Migraine Candidate Gets Priority Review From FDA

        Teva's (TEVA) biologics license application (BLA) seeking approval for fremanezumab as a preventive treatment for migraine gets priority review from FDA

          Aerie (AERI) Gets Early FDA Approval for Lead Drug Rhopressa

          Aerie (AERI) got a significant boost with the FDA approving its lead drug Rhopressa for the lowering of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, ahead of schedule.

            Allergan Inks Deal to Buy Texas-Based Repros Therapeutics

            Allergan (AGN) signs a definitive contract to acquire Texas-based Repros Therapeutics, which is focused on developing new drugs to treat hormonal and reproductive system disorders.

              3 Drug/Biotech Stocks Up More Than 10% This Week

              The drugs/biotech sector is down this week due to broader market pressure, except a few stocks.

                Roche Reports Positive Data from Tecentriq Combination Study

                Roche reported positive data from a combination study of Tecentriq and Avastin in metastatic renal cell carcinoma patients.

                  3 Drug/Biotech Stocks Up More Than 10% This Week

                  The drugs/biotech sector is down this week due to broader market pressure, except a few stocks.

                    Roche's Avastin Gets Full FDA Approval for Brain Cancer

                    Roche (RHHBY) announced that the FDA converted accelerated approval for Avastin to full approval for the patients previously treated for aggressive form of brain cancer.

                      Revance's Neuromodulator Injection Positive in Phase III

                      Revance (RVNC) releases positive top-line data from two pivotal phase III trials, evaluating RT002 for reducing wrinkles between the brows. The studies meet both primary and secondary endpoints.

                        Here's Why Sarepta Stock is Up More Than 70% in 6 Months

                        Sarepta's (SRPT) key product, Exondys 51, and lead pipeline candidate, golodirsen, have put up a good show in the past six months.

                          AstraZeneca's COPD Drug Succeeds in Label Expansion Study

                          AstraZeneca (AZN) releases positive top-line data from a phase IV study, evaluating label expansion of Tudorza for chronic obstructive pulmonary disease with cardiovascular risk factors.

                            Ironwood Succeeds in Diabetic Hypertension Phase II Study

                            Ironwood Pharmaceuticals' (IRWD) pipeline candidate, IW-1973, reduces blood pressure and improves metabolic parameters in type II diabetes with hypertension patients in a phase IIa study.

                              Teva's New CEO Re-Shuffles Senior Management, Stock Up 7%

                              Teva (TEVA) announced several organizational changes in order to save costs and improve productivity.

                                Teva (TEVA) Stock Rises 5% on Reports of Massive Job Cuts

                                Per an Israeli news release, Teva (TEVA) is expected to lay off 4000 employees

                                  Allergan's Vraylar Gets FDA Nod for Maintenance Therapy

                                  Allergan's (AGN) schizophrenia capsule, Vraylar, secures an FDA approval for its label expansion as a maintenance treatment option in the market.

                                    Amgen Gets Positive CHMP Opinion to Expand Nplate's Label

                                    Amgen (AMGN) received positive CHMP opinion to expand Nplate's label to include pediatric patients and also for the marketing application of Avastin biosimilar.

                                      Aerie (AERI) Q3 Loss Wider Than Expected, Pipeline in Focus

                                      Increased operating expenses mar Aerie's (AERI) Q3 performance.

                                        Key Predictions for Q3 Earnings Reports of PBYI, XON, LGND

                                        The pharma/biotech industry has witnessed strong Q3 results with many companies beating estimates for earnings and sales. Let's see if some small biotechs, due to report on Nov 9, follow suit.

                                          Ironwood (IRWD) Beats Estimates in Q3 Earnings, Stock Up

                                          Ironwood Pharmaceuticals (IRWD) beats estimates on both counts in the third quarter. Demand for Linzess rises.

                                            Teva (TEVA) Stock Plunges 20% on Q3 Earnings Miss & View Cut

                                            Teva's (TEVA) third-quarter earnings missed estimates while revenues were in line. The company lowered its earnings and revenue guidance for 2017, for the second time this year.

                                              Key Predictions for Q3 Earnings Reports of MYL, HZNP & KERX

                                              The pharma/biotech industry has witnessed strong Q3 results with many companies beating estimates for earnings and sales. Let's see if generic maker Mylan and other small companies follow suit.

                                                Allergan (AGN) Tops Q3 Earnings Estimates, Tweaks 2017 View

                                                Allergan (AGN) beat expectations for earnings while delivering in-line revenues in Q3. While the company slightly lowered its sales guidance, it raised the upper end of the earnings guidance.

                                                  Allergan (AGN) Beats Q3 Earnings, Sales In Line, Stock Up

                                                  Allergan plc (AGN) beat expectations for earnings while delivering in-line revenues in Q3. Revenues rose 11.4% year over year.